Gastric inhibitory peptide receptor ligands with biodistribution modifiers
A cyclic peptide with tailored N- and C-terminal modifications addresses the limitations of existing GIPR-targeting agents by improving biodistribution and therapeutic index, enabling effective diagnosis and treatment of GIPR-expressing diseases like neuroendocrine tumors.
JP2026518415APending Publication Date: 2026-06-083B PHARM GMBH
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- 3B PHARM GMBH
- Filing Date
- 2024-04-25
- Publication Date
- 2026-06-08
Smart Images
Figure 2026518415000001_ABST
Abstract
The present invention relates to a compound comprising a cyclic peptide represented by formula (Ia) or a cyclic peptide represented by formula (Ib), each comprising an N-terminal modifying group A containing a biodistribution modifier, the N-terminal modifying group A being bonded to Xaa1, and each comprising a C-terminal group C-term containing a biodistribution modifier, the C-terminal group C-term being bonded to Xaa11.
Need to check novelty before this filing date? Find Prior Art